RT Journal Article
SR Electronic
A1 Alexander, Lori
T1 Pasireotide May Provide Option for Medical Therapy Targeting the Underlying Cause of Cushing Disease
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 5
SP 12
OP 12
DO 10.1177/155989771105007
UL http://mdc.sagepub.com/content/11/5/12.abstract
AB A Phase 3 trial showed that pasireotide, a multireceptor-targeted somatostatin analog, led to rapid and sustained decreases in cortisol levels and provided clinical benefit in patients with Cushing disease. Surgery is the first-line treatment for this disease, and most current medical options block adrenal cortisol production but do not treat the underlying disease. Pasireotide may provide the first reliable pituitary-directed medical therapy that targets the underlying cause of Cushing disease.